MEDDAY
MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.
MEDDAY
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2011-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.medday-pharma.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
48.96 M USD
Technology used in webpage:
SPF Domain Not Resolving Mobile Non Scaleable Content Nginx Gravatar Profiles DigiCert SSL Java EE Smart App Banner OVH GeoTrust SSL
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series B - MedDay
InnoBio
InnoBio investment in Series B - MedDay
Bpifrance
Bpifrance investment in Series B - MedDay
Sofinnova Partners
Sofinnova Partners investment in Series B - MedDay
Sofinnova Partners
Sofinnova Partners investment in Series A - MedDay
Newest Events participated
Official Site Inspections
http://www.medday-pharma.com
- Host name: ip110.ip-142-44-251.net
- IP address: 142.44.251.110
- Location: Montreal Canada
- Latitude: 45.5063
- Longitude: -73.5794
- Timezone: America/Toronto
- Postal: H3A
More informations about "MedDay"
MedDay Pharma - Dare to Explore | Medday-Pharma.com
Committed to patients, our passionate teams are investigating brain metabolism therapies, utilizing an innovative approach, with the goal of transforming the lives of people affected by …See details»
About Us - MedDay Pharma
Investigating neurodegenerative diseases from a different perspective. Our board of directors is composed of leading investors and independent members. Our scientific advisory board is composed of top neurology specialists from all …See details»
Who We Are - MedDay Pharma
At MedDay, we are committed to treating nervous system disorders in areas of high unmet medical need through the elucidation of metabolism pathways in the brain.See details»
MedDay - Crunchbase Company Profile & Funding
MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat …See details»
MedDay Pharmaceuticals SAS - life-sciences-europe.com
Jan 1, 2011 · MedDay is a biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive …See details»
MedDay - Biotech.info
“The story of MedDay began in 2011, when Frédéric Sedel, MD, PhD, a neurologist and neuroscientist met with Guillaume Brion, an entrepreneur with experience in drug …See details»
MedDay Pharmaceuticals SAS - life-sciences-europe.com
Jan 1, 2011 · MedDay is a biotechnology company developing new drugs for nervous system disorders.See details»
MedDay Company Profile - Office Locations, Competitors, …
MedDay is a biotechnology company, which develops new drugs for neurological and psychiatric diseases. It provides MD1003, a solution for the treatment of primary and secondary …See details»
Who We Are - MedDay Pharma
MedDay prioritizes diseases of the central nervous system with high unmet medical need. We place patients and their families at the heart of our mission: our approach is designed to bring …See details»
MedDay Pharmaceuticals Announces Full Patient ... - Business Wire
Nov 9, 2018 · Founded in 2011, MedDay is an international pioneering biopharmaceutical company targeting brain metabolism to treat nervous system disorders. The lead product, …See details»
MedDay report top-line data from trial “SPI2” for treatment of ...
Paris, France, March 10, 2020 – MedDay Pharmaceuticals announced today that the second pivotal Phase III trial (SPI2) of its investigational product MD1003 has not met its primary and …See details»
MedDay Pharmaceuticals | Insights
Dec 15, 2017 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
MedDay's multiple sclerosis drug a bust in phase 3
Mar 10, 2020 · Four years ago, MedDay Pharmaceuticals’ multiple sclerosis drug reversed the course of disease in a 150-patient pivotal study. The biotech set out to confirm those results in …See details»
Management team - MedDay Pharma
Anne-Sophie Larivière is Value Strategy Director at MedDay. As part of her work, she focuses on the drivers of value for the key asset of the company as well as on corporate communication.See details»
France’s MedDay says drug for MS falls at phase 3 hurdle
Mar 12, 2020 · MedDay Pharma has been unable to replicate promising results with its multiple sclerosis therapy MD1003 in a confirmatory phase 3 trial, sending the programme back to the …See details»
MedDay misses endpoint in phase III multiple sclerosis vision loss ...
“MedDay will now pursue the development and file MD1003 only in progressive forms of MS, where there is a particular need for a disease modifying therapy and no drug approved so far.” …See details»
Is the Optic Nerve Overdue as a Criterion to Support the
Jul 3, 2023 · The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service. If you need immediate support or to place an …See details»
Comparative effectiveness of teriflunomide vs dimethyl fumarate …
T. Moreau has received fees as scientific adviser from Biogen, MedDay, Novartis, Genzyme, and Sanofi. O. Gout has received in the last year consulting and lecture fees, travel grants, and …See details»
Our story - MedDay Pharma
Origin of the name MedDay. Our company’s name MedDay refers to the «mayday» distress signal, coined by the aeronautics industry in 1923, and derived from the French «m’aider» …See details»
Current and Future Roles of Chimeric Antigen Receptor T-Cell …
3 days ago · Importance Advancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors …See details»